Loading clinical trials...
Loading clinical trials...
Postoperative immunoadjuvant therapy has been proven to significantly reduce the risk of recurrence after resectable NSCLC, and has become a new standard of postoperative adjuvant therapy for stage II...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Kong Fanming
Collaborators
NCT07489716 · Non-Small Cell Lung Cancer
NCT07444437 · Non-Small Cell Lung Cancer
NCT07154290 · Advanced/Metastatic Non-Small Cell Lung Cancer
NCT07300150 · Colorectal Cancer, Pancreatic Cancer, and more
NCT06043817 · Non-Small Cell Lung Cancer, NSCLC, and more
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Tianjin
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions